

Appendix 4E

Preliminary final report

1. Details of reporting period

Name of entity	Cynata Therapeutics Limited (the Company)
ABN	98 104 037 372
Reporting Period	Year ended 30 June 2015
Previous Corresponding Period	Year ended 30 June 2014

2. Results for announcement to the market

Key information	12 months ended 30 June 2015 \$	12 months ended 30 June 2014 \$	Increase/ (decrease) %	Amount change \$
Revenues from ordinary activities	374,889	107,755	247.91	267,134
Loss from ordinary activities after tax attributable to members	3,712,077	3,039,663	22.12	672,414
Net loss for the period attributable to members	3,712,077	3,039,663	22.12	672,414
Net tangible asset/(deficiency) per share	0.066	0.092		

3. Consolidated statement of profit or loss and other comprehensive income

Refer to attached consolidated financial statements.

4. Consolidated statement of financial position

Refer to attached consolidated financial statements.

5. Consolidated statement of cash flows

Refer to attached consolidated financial statements.

6. Consolidated statement of changes in equity

Refer to attached consolidated financial statements.

7. Dividends/Distributions

No dividends declared in current or prior year.

8. Details of dividend reinvestment plans

N/A

9. Details of entities over which control has been gained or lost during the period

N/A

10. Details of associate and joint venture entities

N/A

11. Any other significant information needed by an investor to make an informed assessment of the Company's financial performance and financial position

Refer to attached consolidated financial statements.

12. Foreign entities

Refer to attached consolidated financial statements.

13. Commentary on results for period and explanatory information

Cynata Therapeutics Limited and its controlled entities (the Group) incurred a net loss from operations for the financial year ended 30 June 2015 of \$3,712,077 (2014: \$3,039,633). At 30 June 2015, the Group had a cash balance of \$4,703,689 (2014: \$5,094,582) and net assets of \$8,749,959 (2014: \$9,854,632). The net cash outflow from operating activities for the financial year was \$2,602,346 (2014: \$1,853,693). During the year, the Company continued to develop its proprietary, scalable mesenchymal stem cell (MSC) manufacturing technology, Cymerus™. This technology enables essentially limitless production of therapeutics MSCs and thus will provide a vital key to the commercialisation of MSC-based medicines. The field of MSC-based medicines is developing at a fast pace with clinical trials underway around the world in a range of medically challenging diseases and Cynata is positioned at the forefront of MSC manufacturing with its unique Cymerus™ technology. The exercise of the Company's December 2014 options provided the Company with additional funds to continue its planned operations. For more information, refer to the attached consolidated financial statements.

14. Audit

This report is based on accounts which have been audited and the audit report is included in the attached consolidated financial statements.



Dr Ross Macdonald
Managing Director

21 August 2015